yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

Basilea Initiates Next Phase 1 Multiple Ascending Dose Study With Antibiotic Bal30072 Active Against Multidrug-Resistant Gram-Negative Bacteria

BASEL, SWITZERLAND -- (Marketwire) -- 11/22/12 -- Basilea Pharmaceutica AG / Basilea initiates next phase 1 multiple ascending dose study with antibiotic BAL30072 active against multidrug-resistant Gram-negative bacteria. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the next planned pharmacokinetic phase 1 healthy volunteer study in its clinical development program for BAL30072, Basilea's new investigational antibiotic with activity against multidrug-resistant Gram- negative bacteria.

Gram-negative pathogens account for approximately half of all hospital- acquired bacterial infections. Many Gram-negative pathogens have acquired the ability to produce enzymes that destroy beta-lactam antibiotics, which have been the mainstay of antibiotic therapy for several decades. Multidrug-resistant bacteria for which there are few or no therapeutic options available are being encountered with increasing frequency and are associated with increased mortality, prolonged hospital stays and higher healthcare costs.

BAL30072 is a novel injectable sulfactam antibiotic that in in-vitro and in-vivo models demonstrated potent bactericidal activity against a broad range of clinically relevant multidrug-resistant Gram-negative pathogens such as Pseudomonas or Acinetobacter species. BAL30072 overcomes several mechanisms of bacterial resistance. In particular, it is not easily destroyed by bacterial enzymes such as extended-spectrum beta-lactamases (ESBLs), carbapenemases or the New Delhi metallo-beta-lactamase 1 (NDM-1), which cause resistance to many marketed antibiotics.

Prof. Achim Kaufhold, Chief Medical Officer of Basilea, stated: "Due to its potent antimicrobial activity BAL30072 has the potential to play an essential role in the therapy of serious and life-threatening infections caused by Gram-negative bacteria for which currently only limited therapeutic options exist. We are now expanding our phase 1 clinical program for this promising drug candidate to optimize dosing regimens in preparation for phase 2 clinical studies."

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from

Press release (PDF):

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE [HUG#1659937]

For further information, please contact:

Media Relations

Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations

Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
Using any programming framework to the fullest extent possible first requires an understanding of advanced software architecture concepts. While writing a little client-side JavaScript does not necessarily require as much consideration when designing a scalable software architecture, t...
Test-driven development (TDD) has been around for a while now. Behavior-driven development (BDD), a comparably recent methodology, emerged from the practice of TDD and could reasonably be called a narrower application of TDD. The TDD process allows a developer to use a failing unit t...
Developers generally like to share their code, and many of them do so by open sourcing it on GitHub, a social code hosting and collaboration service. Many companies also use GitHub as a convenient place to host both private and public code repositories by creating GitHub organizations ...
It is no surprise that OpenStack has evolved into a widely adopted cloud management framework. As it hurtles on a trajectory of rapid growth, a new breed of demands are making themselves felt – demands that a mature platform of this nature and scope must satisfy. One such requirement i...
The combined notions of open source and the ‘community contribution’ model of collaborative software application development are, of course, not new. The history of open source is actually traced back to early software exchanges between universities driven by academic principles of kn...
Cloud computing delivers on-demand IT resources that provide businesses flexibility. The challenge is the cost and complexity of cloud security compliance (PCI, HIPAA, FFIEC). Raxak Protect automated cloud security enables cloud apps to be deployed quickly and cost-effectively. Get the...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers